News and Events

Biopharmapress: Combating Sepsis Mortality

European Biotechnology: Fighting sepsis mortality

BioWorld: 4TEEN4 closes $8M A round to test first-in-class cardiogenic shock drug

VC-Magazin: 4TEEN4 Pharmaceuticals sammelt 6.9 Mio. EUR ein

LABIOTECH: German Biotech Raises €7M Series A to Treat Acute Heart Failure

Biotech Startup 4TEEN4 Pharmaceuicals Closes EUR 7 Million Series A Financing

4TEEN4 Pharmaceuticals GmbH (formerly Sphingotec Therapeutics GmbH) announced today the closing of a EUR 6.9 million Series A financing round. The new funds will be used to advance the preclinical development and initiate first-in-man studies of 4TEEN4’s lead antibody candidate Procizumab.

READ MORE ↵


Rehfeld L et al. on Novel Methods for the Quantification of Dipeptidyl Peptidase 3 (DPP3) Concentration and Activity in Human Blood Samples

LABIOTECH: Top Cardiology Biotech News from the ESC Conference 2019

transkript: Berliner Seriengründer präsentiert neues Projekt

European Biotechnology: DPP3 triggers myocardial depression

LABIOTECH: 4TEEN4 Pharmaceuticals reports first results on Procizumab, a novel therapeutic anti-DPP3 antibody for treatment of acute myocardial depression.

4TEEN4 Pharmaceuticals reports first results on Procizumab, a novel therapeutic anti-DPP3 antibody for treatment of acute myocardial depression.

4TEEN4 Pharmaceuticals GmbH today for the first time reported preclinical data on its lead product Procizumab, a therapeutic antibody targeting circulating Dipeptidyl Peptidase 3 (DPP3) for the treatment of patients with acute myocardial depression including acute heart failure and cardiogenic shock.

READ MORE ↵


Deniau B et al. on Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics

Takagi K et al. on Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial

Kaufmann P et al. on A novel and highly efficient purification procedure for native human dipeptidyl peptidase 3 from human blood cell lysate